glp-1 fda shortage declares semaglutide over Fierce Healthcare latest headline is quite provocative. What's your take? How FDA ends GLP-1 shortage. Compounding

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial

Persistent severe nausea is not something patients should endure indefinitely, and PlexusDx providers evaluate alternatives when side effects outweigh benefits

The development of next-generation GLP-1 RAs and dual agonists further expands the therapeutic potential of this drug class in addressing the complex, multisystem consequences of obesity [8]

[Scientist, not medic.] Thick blood

It reflects the pharmacological action of the medication working as designed

Typically, GLP-1s do not affect growth and puberty unless their bodies dont have enough energy for these processes